Results 221 to 230 of about 141,145 (350)

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors

open access: yesAdvanced Science, EarlyView.
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy   +16 more
wiley   +1 more source

Patient and Physician Perspectives on the Management of Diabetic Macular Edema. [PDF]

open access: yesOphthalmol Ther
Warren B   +3 more
europepmc   +1 more source

Reinforcing Calcium Overload via Inflammation‐Mediated Targeting to Amplify Pyroptosis and Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
A neutrophil‐membrane‐camouflaged nanoplatform (RC@NMVs) exploits tumor inflammation to target and accumulate in tumors. Intracellular Ca2+ overload is triggered via lysosomal CaP dissolution and Ru red‐mediated Ca2+ channel blockade, synergistically inducing gasdermin‐mediated pyroptosis.
Yingying Liu   +8 more
wiley   +1 more source

MG53 Coordinates Macrophage Polarization and Neuroimmune Coupling to Promote Corneal Nerve Regeneration via the MPEG1–MVP–STAT6 Axis

open access: yesAdvanced Science, EarlyView.
Corneal nerve regeneration is critical to corneal wound healing processes. The current study reveals a novel role of MG53 in promoting corneal nerve regeneration after alkali induced injury. Mechanistically, MG53 enters macrophages via its receptor, MPEG1, promotes MVP K63 ubiquitination, and triggers STAT6 induced repair‐related genes expression ...
Peng Chen   +14 more
wiley   +1 more source

A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Plastin‐2 (PLS2) is identified as a dual‐function receptor on DCs that mediates both nanoparticle uptake and immunomodulation. A nanobody‐LNP platform is engineered to integrate antigen delivery with relicensing DCs. The therapeutic strategy elicits potent anti‐tumor T cell responses and leads to significant inhibition of established tumors in vivo ...
Shugang Qin   +9 more
wiley   +1 more source

Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care. [PDF]

open access: yesSupport Care Cancer
Johnson WV   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy